Article
Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.
The New England journal of medicine - 30 Oct 2025
Yang James Chih-Hsin, Lu Shun, Hayashi Hidetoshi, Felip Enriqueta, Spira Alexander I, Girard Nicolas, Kim Yu Jung, Lee Se-Hoon, Ostapenko Yurii, Danchaivijitr Pongwut, Liu Baogang, Alip Adlinda, Korbenfeld Ernesto, Mourão Dias Josiane, Besse Benjamin, Passaro Antonio, Lee Ki-Hyeong, Xiong Hailin, How Soon-Hin, Cheng Ying, Chang Gee-Chen, Yoshioka Hiroshige, Thomas Michael, Nguyen Danny, Ou Sai-Hong Ignatius, Mukhedkar Sanjay, Prabhash Kumar, D'Arcangelo Manolo, Alatorre-Alexander Jorge, Vázquez Limón Juan Carlos, Alves Sara, Stroyakovskiy Daniil, Peregudova Marina, Şendur Mehmet Ali Nahit, Yazici Ozan, Califano Raffaele, Gutiérrez Calderón Vanesa, de Marinis Filippo, Kim Sang-We, Gadgeel Shirish M, Owen Scott, Xie John, Sun Tao, Mehta Jaydeep, Venkatasubramanian Raja, Ennis Mariah, Fennema Elizabeth, Daksh Mahesh, Roshak Amy, Man Julie, Knoblauch Roland E, Bauml Joshua M, Baig Mahadi, Shah Sujay, Sethi Seema, Cho Byoung Chul
Abstract excerpt
BACKGROUND: Previous results from this phase 3 trial showed that progression-free survival among participants with previously untreated EGFR (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC) was significantly improved with amivantamab-lazertinib as compared with osimertinib. Results of the protocol-specified final overall survival analysis in this trial have not been reported....
Read the complete abstract on PubMed